Bionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow
23 Janeiro 2023 - 10:01AM
Bionano Genomics, Inc. (BNGO today announced the launch of
multiple new products and advancements for its optical genome
mapping (OGM) workflow that offer enhanced robustness in sample
preparation, decreased turnaround time for DNA labeling and
imaging, and improvements in throughput and quality
metrics. The new versions of Bionano’s sample prep kits, chips and
instrument software address customer feedback and can improve the
performance in routine higher volume genome analysis applications.
Bionano’s sample prep kits are used to extract and label
ultra-high molecular weight (UHMW) DNA for use on the Saphyr®
system. These kits are optimized for performing Bionano
OGM applications on a variety of sample types. Generation 2 kits
will support blood samples, cell lines, and bone marrow aspirates,
with versions for tissue and tumor samples expected later in 2023.
The Bionano Prep SP-G2 (SP-G2) and Bionano Prep Direct Label and
Stain (DLS-G2) kits have also increased in size from 10-reaction to
12-reaction kits, an upgrade that better matches the company’s chip
consumables.
The SP-G2 kit enhances UHMW DNA isolation and enables
higher sample success rates, fewer user errors and more data
generated per run. One of the main improvements to sample
preparation is the potential to isolate DNA of higher quality,
especially for marginal samples. The new protocol also can
eliminate time and process constraints, making the lysis step more
user-friendly and better optimized for runs with different sample
types, which allows users to batch up to six samples
simultaneously. These improvements in chemistry can ultimately
result in increased DNA throughput for more data generated per
sample run. In addition, a derivative of the SP-G2 kit supports
Hamilton’s Long String Vantage automated UHMW DNA isolation.
Bionano’s DLS-G2 kit enables labeling to be completed in
as little as five hours for same-day loading of labeled DNA on the
Saphyr® instrument. This improved chemistry can enable an
overall reduction in turnaround (or sample to answer) time and make
it possible to get high depth answers for cancer samples in as
little as three days. Bionano has increased reagent stability from
nine months to one year for the DLS-G2 kit, to be consistent with
the SP-G2 kit, which can result in less reagent wastage and more
utility over a longer period of time.
The Saphyr Chip® G3.3, a new version of
the instrument control software (ICS v5.3) and a new version of
Bionano Access™ (v.1.7.2), enable improved throughput and success
rates when two Saphyr Chips are loaded in parallel, allowing three
to six more samples to be processed per work week. These
throughput improvements result from a reduction in sample
evaporation and enhance the reliability of sample loading and
performance on the Saphyr instrument. Higher throughput also
results in better first-pass yields and may eliminate the risk of
sample depletion when working with complex, longer scan-time
samples, like those in cancer research or cell bioprocessing. ICS
v5.3 support for the Saphyr Chip G3.3 improves consistency of
throughput across runs as well as alignment robustness.
Erik Holmlin, PhD, president and chief executive officer of
Bionano, commented, “With these product launches we are
significantly expanding the genome analysis capabilities available
to the clinical and translational research communities.
We look forward to seeing customers benefit from these
solutions in the coming months, which we believe can reduce
time-to-results and make OGM performance even better. We believe
these improvements can enable greater detection of structural
variants of all types associated with genetic diseases and complex
disorders like cancer.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic testing
for patients with clinical presentations consistent with autism
spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “may,” “potential,” “will”
and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the potential of the SP-G2 and DLS-G2 kits to
make improvements to sample OGM preparation and result in the
isolation and preparation of DNA with higher size and quality, and
improve sample success rates; the ability of ICS v5.3 and the
Saphyr Chip G3.3 to improve consistency of throughput across runs
as well as alignment robustness; the ability of the Saphyr Chip
G3.3 to prevent sample evaporation and enhance the reliability of
sample loading and performance on the Saphyr instrument, and result
in higher first-pass yields or eliminate the risk of sample
depletion when working with complex, longer scan-time samples; and
the ability of OGM to accurately detect genetic disorders,
including structural variants, copy number variants, repeat
expansions greater than 500bp and Fragile X syndrome, and, as a
single technology, to result in a workflow that is cost-effective,
highly sensitive and has a faster time to results than traditional
cytogenetic methods. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of geopolitical and macroeconomic developments, such as the
ongoing Ukraine-Russian conflict, and related sanctions, and the
COVID-19 pandemic, on our business and the global economy; the
failure of the SP-G2 and DLS-G2 kits to make improvements to sample
OGM preparation and result in the isolation and preparation of DNA
with higher size and quality, and improve sample success rates; the
failure of ICS v5.3 and the Saphyr Chip G3.3 to improve consistency
of throughput across runs as well as alignment robustness; the
failure of the Saphyr Chip G3.3 to prevent sample evaporation and
enhance the reliability of sample loading and performance on the
Saphyr instrument, and result in higher first-pass yields or
eliminate the risk of sample depletion when working with complex,
longer scan-time samples; general market conditions; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; changes in
our strategic and commercial plans; our ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024